{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:43:53Z","timestamp":1792622633632,"version":"4.5.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>This study aimed to investigate the real-world profile of adverse events (AEs) associated with gepant medications in the clinical treatment of migraines by analyzing data collected from the VigiAccess database and the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database. As novel migraine therapies, gepants act by targeting the calcitonin gene-related peptide (CGRP) pathway, demonstrating effective control of migraine attacks and good tolerability. Nonetheless, comprehensive real-world studies on the safety of gepants are still lacking, particularly regarding their safety in large populations, long-term use, and potential adverse reactions in specific groups, which necessitates further empirical research. Leveraging these two international adverse event reporting system databases, we systematically gathered and analyzed reports of AEs related to gepant medications, such as rimegepant. Our focus encompasses but is not limited to severe, new, and rare adverse reactions induced by the drugs, as well as safety issues pertaining to the gastrointestinal, cardiovascular, hepatic, and renal systems. Through descriptive statistical analyses, we assessed the incidence and characteristics of AEs, compared AEs among gepants, and uncovered previously unknown AE information, all with the goal of providing a reference for the selection of clinical treatment regimens and AE monitoring.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>By extracting all AE reports concerning \u201crimegepant\u201d, \u201catogepant\u201d, and \u201cubrogepant\u201d from the VigiAccess and FAERS database since its establishment up to 31 March 2024, a retrospective quantitative analysis was conducted. The reporting odds ratio (ROR) method were used to compare AEs among the three gepants.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the VigiAccess and FAERS databases, 23542 AE reports in total, respectively, were identified as being related to gepant medications. Among gastrointestinal system AEs, rimegepant had the greatest proportion and greatest signal strength; nausea was most severe and had the strongest signal in rimegepant AEs, whereas constipation was most prominent and had the strongest signal in atogepant AEs. In skin and subcutaneous tissue disorders, rash and pruritus were more frequently observed with rimegepant, followed by ubrogepant. Alopecia emerged as a novel AE, being more severe in rimegepant and secondarily in atogepant. Regarding cardiac disorders, the three gepants showed comparable rates of cardiac AEs, yet rimegepant exhibited the strongest AE signal. In musculoskeletal and connective tissue AEs, ubrogepant presented the most positive signals for skeletal muscle AEs. Furthermore, among the rare blood and lymphatic system disorder AEs, rimegepant had the highest number of reports of Raynaud\u2019s phenomenon and the strongest signal. The study also revealed that while reports of AEs involving liver diseases were scarce across the three gepants, severe AEs were detected in clinical trials, highlighting the need for continued, enhanced monitoring of liver system AEs through large-scale datasets.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Gepant medications exhibit similarities and differences in their safety profiles. Analysis of the two databases indicated the presence of AEs across various systems, including gastrointestinal disorders, skin and subcutaneous tissue diseases, musculoskeletal and connective tissue disorders, organ-specific effects, and liver diseases. However, each drug displays distinct incidences and signal intensities for these AEs. Additionally, the study revealed a rare AE in the form of Raynaud\u2019s phenomenon. These findings suggest that during clinical use, individualized medication selection and AE monitoring should be based on the patient\u2019s physiological condition and specific characteristics.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1431562","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T05:02:36Z","timestamp":1722402156000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":37,"title":["Real-world study of adverse events associated with gepant use in migraine treatment based on the VigiAccess and U.S. Food and Drug Administration\u2019s adverse event reporting system databases"],"prefix":"10.3389","volume":"15","author":[{"given":"Qiaofang","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taolin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1111\/head.14417","article-title":"Raynaud's phenomenon associated with calcitonin gene-related peptide receptor antagonists case report","volume":"62","author":"Bedrin","year":"2022","journal-title":"Headache"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1111\/head.13930","article-title":"Safety of rimegepant, an oral CGRP receptor antagonist, plus CGRP monoclonal antibodies for migraine","volume":"60","author":"Berman","year":"2020","journal-title":"Headache"},{"key":"B3","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1111\/head.13496","article-title":"The American headache society's position statement on integrating new migraine treatments into clinical practice - comments","volume":"59","author":"Charles","year":"2019","journal-title":"Headache"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1111\/head.14389","article-title":"Zavegepant nasal spray for the acute treatment of migraine: a Phase 2\/3 double-blind, randomized, placebo-controlled, dose-ranging trial","volume":"62","author":"Croop","year":"2022","journal-title":"Headache"},{"key":"B5","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1046\/j.1468-2982.1993.1303166.x","article-title":"Placebo-controlled clinical trials with ergotamine in the acute treatment of migraine","volume":"13","author":"Dahl\u00f6f","year":"1993","journal-title":"Cephalalgia"},{"key":"B6","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1111\/head.13749","article-title":"The risks or lack thereof of migraine treatments in vascular disease","volume":"60","author":"Diener","year":"2020","journal-title":"Headache"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1016\/S0140-6736(23)01683-5","article-title":"Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA","volume":"402","author":"Dodick","year":"2023","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1056\/NEJMoa1813049","article-title":"Ubrogepant for the treatment of migraine","volume":"381","author":"Dodick","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1056\/NEJMp048016","article-title":"CGRP-receptor antagonists--a fresh approach to migraine therapy?","volume":"350","author":"Durham","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"B10","volume-title":"Eudra Vigilance Expert Working Group (EV-EWG) [EB\/OL]","year":"2008"},{"key":"B11","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/S1474-4422(24)00038-3","article-title":"Global, regional, and national burden of disorders affecting the nervous system, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021","volume":"23","year":"2024","journal-title":"Lancet Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1002\/ana.26072","article-title":"Amylin analog pramlintide induces migraine-like attacks in patients","volume":"89","author":"Ghanizada","year":"2021","journal-title":"Ann. Neurol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S0140-6736(23)01462-9","article-title":"Atogepant, the first oral preventive treatment for chronic migraine","volume":"402","author":"Haanes","year":"2023","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3331024231159366","DOI":"10.1177\/03331024231159366","article-title":"Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: a systematic review and network meta-analysis of phase 3 randomised controlled trials","volume":"43","author":"Haghdoost","year":"2023","journal-title":"Cephalalgia"},{"key":"B15","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.ghir.2007.04.009","article-title":"Administration of capsaicin and isoflavone promotes hair growth by increasing insulin-like growth factor-I production in mice and in humans with alopecia","volume":"17","author":"Harada","year":"2007","journal-title":"Growth Horm. IGF Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"881","DOI":"10.3969\/j.issn.1006-9852","article-title":"Chinese guidelines for the diagnosis and treatment of migraine (2022 edition)","volume":"28","year":"2022","journal-title":"Chin. J. Pain Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/head.14095","article-title":"Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: a randomized phase 1b drug-drug interaction study","volume":"61","author":"Jakate","year":"2021","journal-title":"Headache"},{"key":"B18","doi-asserted-by":"publisher","first-page":"860","DOI":"10.3760\/cma.j.issn.1673-4378.2017.09.021","article-title":"Mechanism of the protective effect of calcitonin gene related peptide on myocardial ischemia\/reperfusion injury","volume":"38","author":"Jiarong","year":"2017","journal-title":"Int. J. Anesth. Resus"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1007\/s00228-022-03347-6","article-title":"Safety evaluation of oral calcitonin-gene-related peptide receptor antagonists in patients with acute migraine: a systematic review and meta-analysis","volume":"78","author":"Lee","year":"2022","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S1474-4422(22)00517-8","article-title":"Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial","volume":"22","author":"Lipton","year":"2023","journal-title":"Lancet Neurol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/s41586-024-07237-y","article-title":"CGRP sensory neurons promote tissue healing via neutrophils and macrophages","volume":"27","author":"Lu","year":"2024","journal-title":"Nature"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e2121","DOI":"10.1212\/WNL.0000000000008944","article-title":"Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy","volume":"94","author":"Mullin","year":"2020","journal-title":"Neurology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1358\/dot.2020.56.12.3211624","article-title":"Rimegepant for the treatment of migraine","volume":"56","author":"Negro","year":"2020","journal-title":"Drugs Today (Barc)."},{"key":"B24","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1080\/14656566.2020.1862793","article-title":"Novel synthetic treatment options for migraine","volume":"22","author":"Negro","year":"2021","journal-title":"Expert Opin. Pharmacother."},{"key":"B25","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s12325-022-02369-x","article-title":"Health state utility mapping of rimegepant for the preventive treatment of migraine: double-blind treatment phase and open label extension (BHV3000-305)","volume":"40","author":"Powell","year":"2023","journal-title":"Adv. Ther."},{"key":"B26","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/S0140-6736(23)01049-8","article-title":"Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Pozo-Rosich","year":"2023","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1097\/00001756-199703240-00015","article-title":"Possible involvement of neuropeptidergic sensory nerves in alopecia areata","volume":"8","author":"Rossi","year":"1997","journal-title":"Neuroreport"},{"key":"B28","doi-asserted-by":"publisher","first-page":"3331024221143538","DOI":"10.1177\/03331024221143538","article-title":"Alopecia as an emerging adverse event to CGRP monoclonal antibodies: cases Series, evaluation of FAERS, and literature review","volume":"43","author":"Ruiz","year":"2023","journal-title":"Cephalalgia"},{"key":"B29","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.regpep.2013.08.001","article-title":"Keratinocytes express cytokines and nerve growth factor in response to neuropeptide activation of the ERK1\/2 and JNK MAPK transcription pathways","volume":"10","author":"Shi","year":"2013","journal-title":"Regul. Pept."},{"key":"B30","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1080\/14740338.2023.2248877","article-title":"Identification of novel signal of Raynaud's phenomenon with Calcitonin Gene-Related Peptide (CGRP) antagonists using data mining algorithms and network pharmacological approaches","volume":"23","author":"Singh","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"B31","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/S1474-4422(24)00025-5","article-title":"Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial","volume":"23","author":"Tassorelli","year":"2024","journal-title":"Lancet Neurol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s10194-019-1007-y","article-title":"The need for new acutely acting antimigraine drugs: moving safely outside acute medication overuse","volume":"20","author":"van Hoogstraten","year":"2019","journal-title":"J. Headache Pain"},{"key":"B33","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1002\/acn3.197","article-title":"A second trigeminal CGRP receptor: function and expression of the AMY1 receptor","volume":"2","author":"Walker","year":"2015","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1002\/phar.2725","article-title":"Alopecia signals associated with calcitonin gene-related peptide inhibitors in the treatment or prophylaxis of migraine: a pharmacovigilance study","volume":"42","author":"Woods","year":"2022","journal-title":"Pharmacotherapy"},{"key":"B35","doi-asserted-by":"publisher","first-page":"4190","DOI":"10.1016\/j.cell.2022.09.024","article-title":"Nociceptor neurons direct goblet cells via a CGRP-RAMP1 axis to drive mucus production and gut barrier protection","volume":"185","author":"Yang","year":"2022","journal-title":"Cell"},{"key":"B36","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S1474-4422(23)00126-6","article-title":"Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: a phase 3, double-blind, randomised, placebo-controlled trial","volume":"22","author":"Yu","year":"2023","journal-title":"Lancet Neurol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"eadg7380","DOI":"10.1126\/sciadv.adg7380","article-title":"Activation of CGRP receptor-mediated signaling promotes tendon-bone healing","volume":"10","author":"Zhao","year":"2024","journal-title":"Sci- Adv."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1431562\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T05:02:41Z","timestamp":1722402161000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1431562\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,31]]},"references-count":37,"alternative-id":["10.3389\/fphar.2024.1431562"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1431562","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,31]]},"article-number":"1431562"}}